• AAPL 166.81
  • TSLA 145.206
  • AMZN 179.51
  • MSFT 407.65
  • INTC 34.395
  • EURUSD 1.0709
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. AS /
  3. GLPG.AS

Galapagos N.V. (GLPG AS) stock market data APIs

€27.58 0.02(0.1%) as of April 23, 2024

Galapagos N.V. Financial Data Overview

27.56
27.58
-
27.6
27.18
26.86-41.92
1 802 M
65 897 K
240 M
2.39
0.021
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'GLPG',
Type: 'Common Stock',
Name: 'Galapagos N.V.',
Exchange: 'AS',
CurrencyCode: 'EUR',
CurrencyName: 'Euro',
CurrencySymbol: '€',
CountryName: 'Netherlands',
CountryISO: 'NL',
ISIN: 'BE0003818359',
CIK: NULL,
EmployerIdNumber: '',
FiscalYearEnd: 'December',
IPODate: '2005-05-06',
InternationalDomestic: 'International/Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
}

Galapagos N.V. Fundamental Data is available in our Financial Data APIs

  • Net Revenue 240 M
  • EBITDA -57 299 000
  • Earnings Per Share -0.06
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Galapagos N.V. Earnings via APIs

  • Latest Release 2024-02-23
  • EPS/Forecast -3.93

Get Galapagos N.V. End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Galapagos N.V. latest news via APIs

Galapagos NV (NASDAQ:GLPG) Q4 2023 Earnings Call Transcript

Galapagos NV (NASDAQ:GLPG) Q4 2023 Earnings Call Transcript February 23, 2024 Galapagos NV beats earnings expectations. Reported EPS is $2.39, expectations were $-2.23. Galapagos NV isn’t one of th...

Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline

Frontier Medicines - First participant dosed in Phase 1/2 PROSPER trial of FMC-376 in KRASG12C Cancers - FMC-376 is a first-in-class direct dual inhibitor of ON+OFF KRASG12C - FMC-376 has the pot...
Do you have any questions?
support@eodhistoricaldata.com